A Clinical Study of T3011 in Subjects With Advanced Melanoma

This trial is testing T3011, an experimental cancer drug, in people with advanced melanoma (skin cancer that has spread). T3011 is a type of modified oncolytic virus — a specially engineered virus that selectively infects and destroys cancer cells while also activating the immune system to attack the tumor. **You may be eligible if...** - You have been diagnosed with advanced melanoma - You have at least one tumor that can be measured - You are in reasonably good physical health and able to carry out daily activities - Your expected survival is more than 12 weeks - Women of childbearing age must have a negative pregnancy test and use contraception during and for 6 months after the study - Male participants must also use contraception and not donate sperm during this period **You may NOT be eligible if...** - You have received certain other cancer treatments too recently before enrollment - You have had another cancer diagnosis within a certain time period - You have significant heart problems or cardiovascular disease - You have an active infection requiring IV antibiotics - You have an autoimmune disease or a history of one - You have fluid buildup around your lungs, heart, or abdomen (pleural, pericardial effusion, or ascites) - You have significant psychiatric conditions that may affect your ability to participate Talk to your doctor to see if this trial is right for you.